Sacubitril
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2015
- First approval year
- 2015
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Sacubitril
- Molecular weight
- 411.5
- Structure (SMILES)
- CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O
- sacubitril component of entresto
- Sacubitril component of entresto
- ahu 377
- AHU-377
- ahu377
- AHU377
- entresto component sacubitril
- ENTRESTO COMPONENT SACUBITRIL
- sacubitril
- Sacubitril
- sacubitril [INN]
- SACUBITRIL [JAN]
- SACUBITRIL [MI]
- SACUBITRIL [ORANGE BOOK]
- SACUBITRIL [USAN]
- Sacubitril [WHO-DD]
- sacubitril inn
- sacubitril jan
- sacubitril mi
- sacubitril orange book
- sacubitril usan
- sacubitril who dd
- sacubitrilo
- Sacubitrilo
- CAS registry numbers
- 149709-62-6
- ChEMBL ID
- CHEMBL3137301
- InChIKey
- PYNXFZCZUAOOQC-UTKZUKDTSA-N
- PubChem compound IDs
- 9811834
- RxNorm IDs (RxCUI)
- 1656328
- FDA ingredient codes (UNII)
- 17ERJ0MKGI
- Applicant
- NOVARTIS PHARMS CORP
- Approval date
- 7 Jul 2015
- Application number
- NDA207620
- First in class
- Yes
- Orphan designation
- No
- Availability
- Prescription only
- Pharmacology name
- sacubitril
- Type
- Synthetic organic
- Drug name stem
- -tril
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
Mechanisms of action
- Mechanism
- Neprilysin inhibitor
- Action type
- Inhibitor
- Target
- Neprilysin
- Protein identifier
- P08473
Open Targets mechanisms
- Mechanism
- Neprilysin inhibitor
- Action type
- Inhibitor
- Target
- Neprilysin
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- MME
- Protein identifier
- P08473
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Heart Failure
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000373
- Subject identifier
- D006333
- Condition
- Hypertension
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Cardiomyopathy, Hypertrophic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000538
- Subject identifier
- D002312
- Condition
- Myocardial Infarction
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000612
- Subject identifier
- D009203
- Condition
- Heart Failure
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003144
- Subject identifier
- D006333
- Condition
- Peripheral Arterial Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004265
- Subject identifier
- D058729
- Condition
- Chagas Cardiomyopathy
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005529
- Subject identifier
- D002598
- Condition
- Aortic Valve Insufficiency
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007148
- Subject identifier
- D001022
- Condition
- Myocardial Infarction
- Highest recorded phase
- 3
- Condition identifier
- EFO:0008583
- Subject identifier
- D009203
- Condition
- ST Elevation Myocardial Infarction
- Highest recorded phase
- 3
- Condition identifier
- EFO:0008585
- Subject identifier
- D000072657
- Condition
- Essential Hypertension
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001134
- Subject identifier
- D000075222
- Condition
- Hypertension, Pulmonary
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005149
- Subject identifier
- D006976
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000373
- Condition identifier
- EFO_0000537
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000538
- Condition identifier
- EFO_0000612
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003144
- Condition identifier
- EFO_0003896
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004265
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005109
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005529
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007148
- Highest recorded phase
- 2
- Condition identifier
- EFO_0008583
- Condition identifier
- EFO_1001207
- Condition identifier
- HP_0000822
- Highest recorded phase
- 3
- Condition identifier
- HP_0001513
- Highest recorded phase
- 2
- Condition identifier
- HP_0011105
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001134
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004781
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004995
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005009
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005044
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005045
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005062
- Condition identifier
- MONDO_0005068
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005149
- Highest recorded phase
- 3
And 13 more, listed on the interactive page.
- Event
- angioedema
- Reports
- 419
- Reporting signal score
- 308.144
- Event
- blood creatinine increased
- Reports
- 586
- Reporting signal score
- 546.593
- Event
- blood potassium increased
- Reports
- 359
- Reporting signal score
- 696.548
- Event
- blood pressure decreased
- Reports
- 580
- Reporting signal score
- 684.134
- Event
- cardiac failure
- Reports
- 896
- Reporting signal score
- 1,316.37
- Event
- cardiac failure chronic
- Reports
- 142
- Reporting signal score
- 343.147
- Event
- cough
- Reports
- 990
- Reporting signal score
- 530.903
- Event
- dizziness
- Reports
- 1,622
- Reporting signal score
- 727.857
- Event
- dyspnoea
- Reports
- 1,671
- Reporting signal score
- 599.075
- Event
- ejection fraction decreased
- Reports
- 437
- Reporting signal score
- 809.682
- Event
- fluid retention
- Reports
- 298
- Reporting signal score
- 271.656
- Event
- glomerular filtration rate decreased
- Reports
- 196
- Reporting signal score
- 307.884
- Event
- hyperkalaemia
- Reports
- 502
- Reporting signal score
- 610.196
- Event
- hypoacusis
- Reports
- 219
- Reporting signal score
- 274.203
- Event
- hypotension
- Reports
- 3,162
- Reporting signal score
- 4,724.33
- Event
- injection site pain
- Reports
- 1
- Reporting signal score
- 271.009
- Event
- n-terminal prohormone brain natriuretic peptide increased
- Reports
- 108
- Reporting signal score
- 317.289
- Event
- renal impairment
- Reports
- 486
- Reporting signal score
- 322.603
- Event
- weight decreased
- Reports
- 639
- Reporting signal score
- 227.895
- Event
- weight increased
- Reports
- 596
- Reporting signal score
- 279.265
- Event
- wrong technique in product usage process
- Reports
- 739
- Reporting signal score
- 532.606
- NCT00549770
- NCT01281306
- NCT01870739
- NCT04637152
- NCT05545059
- NCT02554890
- NCT02754518
- NCT02787798
- NCT02874794
- NCT02887183
- NCT02900378
- NCT02970669
- NCT03005184
- NCT03066804
- NCT03119623
- NCT03168568
- NCT03300427
- NCT03552575
- NCT03785405
- NCT03988634
- NCT04103554
- NCT04128891
- NCT04572724
- NCT04688294
- NCT05164653
And 18 more, listed on the interactive page.
- Dose
- 49 mg/51 mg
- Route
- Oral
- How often
- Twice daily
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 2
- Polar surface area
- 92.7
- Calculated partition coefficient (ALogP)
- 3.84
- Calculated partition coefficient (XLogP)
- 3.7
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 11
- Heavy atoms
- 30
- Molecular formula
- C24H29NO5
- Monoisotopic mass
- 411.20457303
- Natural product
- Yes
- 0078-0659
- 0078-0696
- 0078-0777
- 0078-1231
- 0078-1238
- 0078-9659
- 0078-9777
- 0904-7580
- 0904-7581
- 0904-7582
- 13668-634
- 13668-635
- 13668-636
- 13668-746
- 13668-747
- 31722-673
- 31722-674
- 31722-675
- 33342-570
- 33342-571
- 33342-572
- 42385-930
- 42385-931
- 42385-932
- 43598-643
And 75 more, listed on the interactive page.
- Recorded assays
- 24
- Active assays
- 0
Related records
Trials (119)
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
- A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data
- A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension
- A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
- A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
- A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
- A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension
- An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
- Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.
- Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation
- ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling
- ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure
- Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto® (Sacubitril and Valsartan) Tablets (97 mg/103 mg)
- Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
- Changes in the T-wave Alternans in Patients With Heart Failure Treated Wih Sacubitril-Valsartan
- Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure
- Comparing ARNI With ACE Inhibitor on Endothelial Function
Approved for (2)
- Congestive heart failure
- Heart failure
In development for (11)
- Acute myocardial infarction Phase 3
- Aortic valve insufficiency Phase 2
- Chagas cardiomyopathy Phase 3
- COVID-19 Phase 1
- Essential hypertension Phase 2
- Hypertensive disorder Phase 3
- Hypertrophic cardiomyopathy Phase 2
- Myocardial infarction Phase 3
- Peripheral arterial disease Phase 2
- Pulmonary hypertension Phase 3
- ST-elevation myocardial infarction Phase 3
Other linked conditions (1)
- Systolic heart failure
Targets (1)
- MME Neprilysin inhibitor